The merger is expected to close by the first quarter of 2025, pending approval from Denali’s shareholders, regulatory clearances, and other customary closing conditions.
Semnur Pharmaceuticals $2.5B Merger : Legal Representation and Next Steps
The Paul Hastings team advising Semnur includes partners Jeff Hartlin and Elizabeth Razzano. Although complete details of Winston & Strawn LLP’s legal team advising Denali Capital were not immediately available, their involvement highlights the complexity and importance of this SPAC transaction.
Denali, a blank-check company, aims to take private companies public through mergers, thereby providing them with capital and market access. This merger will allow Semnur to further develop and potentially commercialize its innovative non-opioid pain therapy, SP-102, marking a significant milestone in the company’s journey.
Representatives for Denali could not be immediately reached for comment on Tuesday.
